Pierre Ernst, MD; Andrew McIvor, MD; Francine M. Ducharme, MD; Louis-Philippe Boulet, MD; Mark FitzGerald, MB; Kenneth R. Chapman, MD; Tony Bai, MD; Canadian Asthma Guideline Group
Long-acting Î²-agonists are a pillar of therapy for many patients with asthma because they are the preferred add-on therapy to inhaled corticosteroids. However, a recent meta-analysis documented a substantial increase in severe exacerbations requiring hospital admission and life-threatening asthma exacerbations in patients treated with long-acting Î²-agonists. A careful evaluation of this meta-analysis raises several concerns about its applicability to current practice. Pivotal trials evaluating the benefit of adding long-acting Î²-agonists to inhaled corticosteroids were not included. The authors of the current paper call for physicians to continue their usual practice of using long-acting Î²-agonists as adjunctive therapy, as well as for an independent meta-analysis of individual patients using inhaled corticosteroids and long-acting Î²-agonists concomitantly.
Learn more about subscription options.
Register Now for a free account.
Ernst P, McIvor A, Ducharme FM, Boulet L, FitzGerald M, Chapman KR, et al. Safety and Effectiveness of Long-Acting Inhaled β-Agonist Bronchodilators When Taken with Inhaled Corticosteroids. Ann Intern Med. 2006;145:692-694. doi: 10.7326/0003-4819-145-9-200611070-00012
Download citation file:
Published: Ann Intern Med. 2006;145(9):692-694.
Asthma, Hospital Medicine, Prevention/Screening, Pulmonary/Critical Care.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only